Eli Lilly rises after signing $1.3 billion deal with Superluminal

** Shares of drugmaker Eli Lilly LLY.N rise 3.2% to $681.39 in afternoon trade

** Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases

** Boston-based startup Superluminal to receive payments, equity investment, royalties

** Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm

** Separately, Tiger Global Management raises share stake in Lilly by 13.2% to 1.5 million shares

** Including session's moves, stock down 11.8% YTD